CLINICAL AND PATHOGENIC RELATIONSHIP BETWEEN CHRONIC HEART FAILURE, TYPE 2 DIABETES MELLITUS AND OSTEOPOROSIS

Aim.. To study clinical and pathogenic relationships between the development of chronic heart failure (CHF) of ischemic genesis associated with type 2 diabetes mellitus (DM) and osteoporosis in postmenopausal women and to evaluate the effects of anti-osteoporotic therapy on CHFMethods

Methods. A total of 178 women were recruited in the study. All patients were assigned to three groups: Group 1 (n = 48) women with CHF and type 2 DM, Group 2 (n = 93) – women with osteoporosis and CHF, Group 3 (n = 37) women with osteoporosis, heart failure and type 2 diabetes mellitus. The control group comprised 35 healthy women in postmenopausal period without clinical signs and symptoms of cardiovascular disease, diabetes and osteoporotic process. 35 patients in Group 2 received bisphosphonates for the treatment of osteoporosis. Serum levels of tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β) and osteoprotegerin were measured with the ELISA.

Results. A significant inverse correlation between levels of total cholesterol, triglycerides and low-density lipoproteins, blood pressure, and bone mineral density has been found. Levels of TNF-α and IL-1β were significantly higher in Group 3 compared with patients in Groups 1 and 2. Women in the control group had significantly lower levels of cytokines compared with patients in all study groups. All women with comorbidities had significantly higher levels of osteoprotegerin compared with the control group. A significant inverse correlation between levels of TNF-α, IL-1β, osteoprotegerin and glycated hemoglobin and bone mineral density has been determined, as well as a direct correlation with the severity of CHF. A significant association between levels of TNF-α and IL-1β, and reduced bone mineral density and unfavorable course of CHF has been established as well. A significant association between bisphosphonates therapy and a favorable course of CHF has been identified.

Conclusion. Increased production of cytokines and osteoprotegerin is of crucial importance for the development of comorbidities, including CHF, type 2 diabetes mellitus and osteoporosis. Understanding of the key mechanisms determining the relationships between these diseases is essential for the development of novel approaches for evaluating risk factors and new methods for prevention and treatment of these diseases.

1. Kraemer H.C. Statistical issues in assessing comorbidity. Stat Med. 1995; 14: 721-723.

2. Van den Akker M., Buntinx F., Roos S., Knottnerus J.A. Comorbidity or multimorbidity: what’s in a name? A review of the literature. Eur J Gen Pract. 1996; 2 (2): 65-70.https://doi.org/10.3109/13814789609162146

3. Guiding principles for the care of older adults with multimorbidity: an approach for clinicians: American Geriatrics Society Expert Panel on the Care of Older Adults with Multimorbidity. J Am Geriatr Soc. 2012; 60(10):E1-E25. doi: 10.1111/j.1532-5415.2012.04188.x.

4. Shirinsky V.S., Shirinsky I.V. Comorbid disease as an important problem of clinical medicine. The Siberian Medical Journal. 2014; 29 (1): 7-12. (In Russ)

5. Association of cardiometabolic multimorbidity with mortality. JAMA. 2015; 314 (1): 52-60. doi: 10.1001/jama.2015.7008.

6. Kongkaew C., Noyce P.R., Ashcroft D.M. Hospital admissions associated with adverse drug reactions: a systematic review of prospective observational studies. Ann Pharmacother. 2008; 42 (7): 1017-1025. doi: 10.1345/aph.1L037

7. Zhang M., Holman C.D., Price S.D., Sanfilippo F.M., Preen D.B., Bulsara M.K. Comorbidity and repeat admission to hospital for adverse drug reactions in older adults: retrospective cohort study. BMJ. 2009; 338: a2752. doi: 10.1136/bmj.a2752.

8. Garcia-Olmos L., Salvador C.H., Alberquilla A., L. David, C. Montserrat, G.-S. Pilar et al. Comorbidity patterns in patients with chronic diseases in general practice. PLoS One. 2012; 7(2): e32141. doi: 10.1371/journal.pone.0032141

9. Bliuc D., Nguyen N.D., Milch V.E., Nguyen T.V., Eisman J.A., Center J.R. Mortality risk associated with low-trauma osteoporotic fracture and subsequent fracture in men and women. JAMA. 2009; 301 (5): 513-521. doi: 10.1001/jama.2009.50.

10. Teplyakov A.T., Bolotskaya L.A., Stepatcheva T.A., Karaman N.V., Rybal’chenko E.V., Shilov S.N., Maslov A.P. Suppressive Effect of Recombinant Immunomodulator Ronkoleukinonthe Blood Levelof Antiinflammatory Cytokines, Anticardiolipin Autoantibodies and Heart Failure. Kardiologiia. 2008; 48 (8): 34-40. (In Russ)

11. Farhat G.N., Cauley J.A. The link between osteoporosis and cardiovascular disease. Clin Cases Miner Bone Metab. 2008; 5: 19-34.

12. Anagnostis P., Karagiannis A., Kakafika A.I., Tziomalos K., Athyros V.G., Mikhailidis D.P. Atherosclerosis and osteoporosis: age-dependent degenerative processes or related entities? Osteoporos Int. 2009; 20: 197-207. doi: 10.1007/s00198-008-0648-5

13. Farhat G.N., Newman A.B., Sutton-Tyrrell K., Matthews K.A., Boudreau R., Schwartz A.V., et al. The association of bone mineral density measures with incident cardiovascular disease in older adults. Osteoporos Int. 2007; 18: 999-1008. doi: 10.1007/s00198-007-0338-8

14. Den Uyl D., Nurmohamed M.T., van Tuyl L.H., Raterman H.G., Lems W.F. (Sub)clinical cardiovascular disease is associated with increased bone loss and fracture risk; a systematic review of the association between cardiovascular disease and osteoporosis. Arthritis Res Ther. 2011; 13: R5. doi: 10.1186/ar3224

15. Mezquita-Raya P., de la Higuera M., Garcı´a D.F., Alonso G., RuizRequena M.E., de Dios Luna J. et al. The contribution of serum osteoprotegerin to bone mass and vertebral fractures in postmenopausal women. Osteoporos Int. 2005; 16: 1368-1374. doi: 10.1007/s00198-005-1844-1

16. Lampropoulos C.E., Kalamara P., Konsta M., Papaioannou I., Papadima E., Antoniou Z. et al. Osteoporosis and vascular calcification in postmenopausal women: a cross-sectional study. Climacteric. 2016; 19: 303307. doi: 10.3109/13697137.2016.1164134

17. Seven A., Yuksel B., Kabil K.S., Yavuz G., Polat M., Unlu B.S., Keskin N. The evaluation of hormonal and psychological parameters that affect bone mineral density in postmenopausal women. Eur Rev Med Pharmacol Sci. 2016; 20: 20-25.

18. Tanko L.B., Christiansen C., Cox D.A., Geiger M.J., McNabb M.A., Cummings S.R. Relationship between osteoporosis and cardiovascular disease in postmenopausal women. J Bone Miner Res. 2005; 20: 1912-1920. doi: 10.1359/JBMR.050711

19. Rubin M.R., Silverberg S.J. Vascular calcification and osteoporosisthe nature of the nexus. J Clin Endocrinol Metab. 2004; 89: 4243-4245. doi: 10.1210/jc.2004-1324

20. Fiore C.E., Pennisi P., Pulvirenti I., Francucci CM.Bisphosphonates and atherosclerosis. J Endocrinol Invest. 2009; 32: 38-43.

21. Strandberg T.E. Alendronate, osteoporosis, and atherosclerosis. Arch Intern Med. 2008; 168: 2386-2387. doi: 10.1001/archinte.168.21.2386-c

22. Ariyoshi T., Eishi K., Sakamoto I., Matsukuma S., Odate T. Effect of etidronic acid on arterial calcification in dialysis patients. Clin Drug Investig. 2006; 26: 215-222.

23. Kang J.H., Keller J.J., Lin H.C. Bisphosphonates reduced the risk of acute myocardial infarction: a 2-year follow-up study. Osteoporos Int. 2013; 24: 271-277. doi: 10.1007/s00198-012-2213-5

24. Horowitz M. Matrix proteins versus cytokines in the regulation of osteoblast function and bone formation. Calcif Tissue Int. 2003; 72: 5-7. https://doi.org/10.1007/s00223-002-1048-z

25. Shapses S.A., Pop L.C., Wang Y. Obesity is a concern for bone health with aging. Nutr Res. 2017; 9: 1-13. doi: 10.1016/j.nutres.2016.12.010